ImmunityBio Gets FDA Authorization for Breast-Cancer Study
June 15 2021 - 7:44AM
Dow Jones News
By Matt Grossman
ImmunityBio Inc. has received authorization from the Food and
Drug Administration to conduct a Phase 1b/2 study on whether its
Anktiva drug can be an effective addition to standard chemotherapy
and Trodelvy in patients with a form of breast cancer.
The study is directed at patients whose breast cancer hasn't
responded to other treatments. Only a third of third-line patients
respond to Trodelvy alone, and less than 17% continue to respond
after a year.
The addition of Anktiva could help fill a treatment gap if it is
effective, ImmunityBio Executive Chairman Patrick Soon-Shiong said.
Under the planned treatment, Trodelvy would work by targeting a
protein displayed by many cancer cells, while Anktiva would
"recruit" a patient's immune system to continue fighting the tumor,
ImmunityBio said.
The planned study will enroll a maximum of 79 subjects.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
June 15, 2021 07:30 ET (11:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
ImmunityBio (NASDAQ:IBRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunityBio (NASDAQ:IBRX)
Historical Stock Chart
From Sep 2023 to Sep 2024